Form 4: Royalty Pharma Director Vlad Coric Receives Stock Award

Director Vlad Coric of Royalty Pharma plc reports acquisition of Class A Ordinary Shares through a restricted stock unit award.

Summary

• Vlad Coric, a director of Royalty Pharma plc, filed a Form 4 disclosing changes in beneficial ownership.
• On May 13, 2025, Coric acquired 7,614 Class A Ordinary Shares through an award of restricted stock units.
• These restricted stock units vest 100% on the earlier of the one-year anniversary of the grant date or the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date.
• Following the transaction, Coric beneficially owns 10,798 Class A Ordinary Shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options to a director is generally viewed as a positive sign, indicating confidence in the company's future performance. However, it's a routine transaction.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units are subject to the terms of the 2020 Independent Director Equity Incentive Plan, suggesting continued equity-based compensation for directors.

Industry Context

Equity compensation is a common practice in the pharmaceutical industry to align the interests of directors and shareholders.

Stakeholder Impact

• The stock award could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Royalty Pharma, Director, Vlad Coric, Beneficial Ownership, Restricted Stock Units, RPRX, Shares